Articles On Neuren Pharmaceuticals (ASX:NEU)

Title Source Codes Date
Here are the top 10 ASX 200 shares today

The S&P/ASX 200 Index (ASX: XJO) enjoyed another strong session this Wednesday, ploughing further into 8,000-point territory and resetting its all-time record...

Motley Fool NEU 1 day ago
Browse Top 10 ASX 200 Shares Today

Following Monday's market euphoria and fresh all-time highs, it was only natural for the S&P/ASX 200 Index (ASX: XJO) to experience a bit of a correction on Tuesday. Indeed, that's precisely what transpired, with the ASX 200 slipping by...

Kalkine Media NEU 2 days ago
Here are the top 10 ASX 200 shares today

After yesterday's market euphoria and fresh all-time highs, it was only natural that the S&P/ASX 200 Index (ASX: XJO) endured a bit of a jolt back to earth this...

Motley Fool NEU 2 days ago
Investors’ sneak peek at biotech’s bright future

The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors  Day one focus on new opportunities, finding the next blockbuster drug and re...

Stockhead NEU 6 days ago
These top ASX 200 growth shares could rise 20% to 45%

Fortunately for growth investors, there are a lot of quality options for them to choose from on the Australian share market. Two ASX 200 growth shares that have been rated as top buys by brokers are listed below. Here's what they are saying...

Motley Fool NEU 1 week ago
Shares vs. property: Which stocks and suburbs delivered the best growth in FY24?

If you were invested in ASX 200 shares vs. property in FY24 then you probably did pretty well. The S&P/ASX 200 Index (ASX: XJO) rose by 7.83% in FY24, and if we add dividends on top, the total return was a median 12.1%. Meanwhil...

Motley Fool NEU 1 week ago
Bell Potter names 3 of the best ASX 200 stocks to buy in July

If you're in the market for some new ASX 200 shares in July, then it could be worth listening to what analysts at Bell Potter are saying. That's because they have just revealed their favoured picks for the month ahead. Three on its list t...

Motley Fool NEU 1 week ago
Best 3 ASX 200 healthcare shares for price growth in FY24

In this article, we examine the best ASX 200 healthcare shares of FY24 based on share price growth. Here are the best performers, according to data from S & P Global Market Intelligence. The top 3 ASX 200 healthcare shares of FY2...

Motley Fool NEU 1 week ago
Shares vs. property: Which delivered the best growth in FY24?

When we compare the capital growth of ASX 200 shares vs. property in FY24, bricks and mortar comes out on top… but only just. The S&P/ASX 200 Index (ASX: XJO) rose from a closing value of 7,203.3 points on the last trading day of FY...

Motley Fool NEU 2 weeks ago
Where to invest $10,000 in ASX 200 shares in July

If you are lucky enough to have $10,000 burning a hole in your pocket, it could be worth putting it to work in the share market. After all, over the long term, the share market has generated an average return of approximately 10% per annum....

Motley Fool NEU 2 weeks ago
3 of the best ASX 200 stocks to buy in FY25

A new financial year is on the horizon, so what better time to make some new additions to your investment portfolio. But which ASX 200 stocks could be buys? Let's take a look at three best buys for FY 2025 according to analysts at Bell Pott...

Motley Fool NEU 2 weeks ago
Here are the top 10 ASX 200 shares today

It was a decent end to what was a tough trading week for ASX shares and the S&P/ASX 200 Index (ASX: XJO) this Friday. After suffering a few drops this week, investors turne...

Motley Fool NEU 2 weeks ago
ScoPo’s Powerplays: ASX health stocks end the week ahead despite freaky inflation data

ASX health stocks rise in past five days, despite May uptick in inflation  Healius downgrades guidance for FY24, citing inflationary pressures Immutep falls despite positive results from Phase 2 trial in first line head and neck cancer He...

Stockhead NEU 2 weeks ago
Here are the top 10 ASX 200 shares today

It was an unpleasant Wednesday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares this hump day. After enjoying a strong session yesterday, investors reversed course to...

Motley Fool NEU 3 weeks ago
Equity Mates: Buy or sell with Gary Rollo    

I joined Adam Keily on the ‘Equity Mates’ podcast to discuss eight small-cap stocks, share my insights on their performance and answer whether I would buy or sell them. In this episode, we delve into the factors influencing each company pro...

Montgomery NEU 1 month ago
3 reasons to be positive on ASX 200 shares in FY25 (and 3 to be wary)

Vinay Ranjan from Airlie Funds Management says investors should ignore industry predictions for where ASX 200 shares might go in the new financial year and instead simply focus on buying quality companies. Ranjan says attempting to profi...

Motley Fool NEU 1 month ago
This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

ASX 200 healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU) has posted impressive gains over the past year but one director appears to still see value in today's share price. Neuren shares closed the session on Thursday at $19.31, up...

Motley Fool NEU 1 month ago
2 ASX biotech shares that could be the next Telix Pharmaceuticals

Looking to invest in an ASX biotech share with the potential to become the next Telix Pharmaceuticals Ltd (ASX: TLX)? You're not alone! The S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company has been going from strength to st...

Motley Fool NEU 1 month ago
ScoPo’s (actually Wilkie’s) Powerplays: ASX health stocks fall but Dimerix and Avita soar

ASX health stocks fall in past five days in line with broader markets as investors spooked by hotter than expected inflation Dimerix up 33% for week after inking second exclusive license deal for commercialisation of its Phase 3 kidney dis...

Stockhead NEU 1 month ago
These ASX shares could rise 25% to 35%

If you want to give your investment portfolio a nice boost, then it could be worth considering the ASX shares listed below. That's because they have been named as buys and tipped to rise materially from current levels. Here's what you need...

Motley Fool NEU 1 month ago
Daily ASX Market Close: CPI data a drag – May 29, 2024

The ASX200 didn’t seem to be able to recover from the CPI inflation data (April) read – showing a rise to 3.6 per cent – which was hotter than many had forecast. The index lost more than 1.15 per cent – all sectors were down with Consume...

themarketonline.com.au NEU 1 month ago
Why Cettire, Neuren, Peter Warren, and Qantas shares are falling today

The S&P/ASX 200 Index (ASX: XJO) is having a very tough session on Wednesday. In response to the release of a hotter than expected inflation reading, the benchmark index is down 1.35% to 7,661.5 points. Four ASX shares that are falling...

Motley Fool NEU 1 month ago
Neuren says trial shows significant improvements in Pitt Hopkins syndrome

Neuren Pharmaceuticals (ASX:NEU) has reported positive results from a Phase 2 trial of NNZ-2591 in children with Pitt-Hopkins syndrome.

BiotechDispatch NEU 1 month ago
Which ASX biotech shares are pioneering the future of medicine?

ASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial results and strong investor interest are propelling the sector forward. Plenty of upcoming catalysts and company-specific developments could...

Motley Fool NEU 1 month ago
This ASX 200 stock can rocket to a record high: Broker

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price was in fine form on Monday. The ASX 200 pharma stock ended the day almost 16% higher at $23.97. This means that Neuren Pharmaceuticals' shares are now up 78% since this time last year. I...

Motley Fool NEU 1 month ago
5 things to watch on the ASX 200 on Tuesday

On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week in a very positive fashion. The benchmark index rose 0.8% to 7,788.3 points. Will the market be able to build on this on Tuesday? Here are five things to watch: ASX 200 expec...

Motley Fool NEU 1 month ago
Here are the top 10 ASX 200 shares today

The S&P/ASX 200 Index (ASX: XJO) enjoyed a strong start to the trading week this Monday, turning things around from the sour end to last week. The ASX 200 appeared well-rested after the weeken...

Motley Fool NEU 1 month ago
Closing Bell: Rare earths hit launches 300pc small cap moon shot as ASX benchmark beards its bears

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

Stockhead NEU 1 month ago
Why Cettire, Lendlease, Neuren, and Sayona Mining shares are racing higher today

The S&P/ASX 200 Index (ASX: XJO) is having a strong start to the week. In afternoon trade, the benchmark index is up 0.8% to 7,786.8 points. Four ASX shares that are rising more than most today are listed below. Here's why they are ra...

Motley Fool NEU 1 month ago
Guess which ASX 200 healthcare share just rocketed 11% on 'groundbreaking trial'

The S&P/ASX 200 Index (ASX: XJO) is up a very healthy 0.8% today, but this ASX 200  healthcare share is leaving those gains wanting. Shares in the biopharmaceutical company closed on Wednesday trading for $20.71. The stock then...

Motley Fool NEU 1 month ago
CRITERION: Looking for a clinical approach to predicting trial outcomes? AI is there for you

Last Monday marked Clinical Trials Day, when the world’s healing profession celebrated the work of Royal Navy surgeon James Lind. The medical mariner was credited with carrying out the world’s first placebo-controlled clinical trial in 1747...

Stockhead NEU 1 month ago
Closing Bell: Xero takes charge with a 10pc jump; Goldies dive on profit taking

Xero and Nvidia buoyed Tech, while BHP dragged Mining Gold stocks were the worst performing miners today New tensions over China’s drills near Taiwan   The benchmark ASX 200 index was down about -0.50% on Thursday. Xero’s (ASX:XRO) 10% ju...

Stockhead NEU 1 month ago
ASX 200 healthcare stock up 40% in 6 months halted ahead of major trial results

One of the highest growth ASX 200 healthcare stocks on the market went into a trading halt on Thursday. Neuren Pharmaceuticals Ltd (ASX: NEU) requested the trading halt before the market open today. The company said it wanted time t...

Motley Fool NEU 1 month ago
ASX 200 shares vs. property: Which has performed better since the COVID crash?

Do you remember how the COVID-19 market crash began, with ASX 200 shares plummeting almost 700 points in just five trading days? Oh, the shivers up my spine! And that was just the start of it, too. ASX 200 shares vs. property during...

Motley Fool NEU 1 month ago
It’s horses for courses and April was ASX Resources: Selfwealth’s latest best of

I really like being gifted the data drops every month or so from the growing family of madly convenient broker platforms. I am also a huge fan of the ‘democratisation’ of stuff. These trading app-platform-thingys are a fine example. No long...

Stockhead NEU 1 month ago
“Your Stock Request” – 16 May 2024

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Fairmont Equities NEU 2 months ago
Here are the top 10 ASX 200 shares today

The S&P/ASX 200 Index (ASX: XJO) enjoyed a successful hump day this Wednesday, rebounding after some heavy falls earlier in the week. By the end of trading, the...

Motley Fool NEU 2 months ago
Closing Bell: Budget lifts explorers, market newbie Sun Silver up 125pc on debut

ASX gained on the aftermath of Budget Silver stocks on a roll, along with other miners Market newbie Sun Silver hits the ground sprinting on debut   The ASX rose +0.5% on Wednesday on the aftermath of the Fed Budget. The local market also...

Stockhead NEU 2 months ago
Here are the top 10 ASX 200 shares today

It was a dastardly Tuesday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares during today's trading. The ASX 200 finished up with its tail between its legs...

Motley Fool NEU 2 months ago
Closing Bell: Copper stocks are rolling, but not the ASX ahead of Federal Budget and US inflation

ASX retreats on Tuesday ahead of Fed Budget and US PPI/CPI Copper stocks up after the metal hit highest level since 2022 GUD jumps 11pc after strong FY24 update   The ASX dipped by -0.4% on Tuesday ahead of the Federal Budget and a key PP...

Stockhead NEU 2 months ago
Guess which four ASX 300 shares were just re-rated by top brokers

Four S&P/ASX 300 Index (ASX: XKO) shares were just re-rated by top brokers. One operates in the credit-impaired consumer debt segment. The second is a biopharmaceutical company. The third provides vehicle fleet leasing, fleet management...

Motley Fool NEU 2 months ago
ScoPo’s Powerplays: ASX health stocks rise as Polynovo achieves record $10m revenue month

ASX health stock rise  in past five days along with broader markets  Wound care company Polynovo achieves its first ever $10m+ revenue month in April Power says Neuren selloff a “complete overreaction” after US partner Arcadia’s latest res...

Stockhead NEU 2 months ago
Brokers name 3 ASX shares to buy now

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX sha...

Motley Fool NEU 2 months ago
Why Cettire, De Grey Mining, Life360, and Neuren shares are falling today

The S&P/ASX 200 Index (ASX: XJO) has returned to form on Friday. In afternoon trade, the benchmark index is up 0.5% to 7,759.5 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's why they...

Motley Fool NEU 2 months ago
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 2

Imricor has two upcoming pivotal trials and is looking to transform cardiac ablation procedures  Botanix Pharmaceuticals is expecting US FDA approval for its lead dermatology product Sofdra in late June Bell Potter is confident in Paradigm...

Stockhead NEU 2 months ago
Closing Bell: ASX fleeced as retail stocks plunge; Alliance Nickel soars on great big grant

ASX losses accelerate after sluggish retail sector updates  Baby Bunting, Temple & Webster, JB Hi-fi all under pressure on soft sales Alliance Nickel soars on fat federal grant   After opening modestly higher this morning, the ASX qui...

Stockhead NEU 2 months ago
Why this high-flying ASX 200 healthcare stock just crashed 11%

It was the ASX 200 healthcare stock of the year in 2023, with its share price catapulting 214% in just 12 months. But today is a challenging one for Neuren Pharmaceuticals Ltd (ASX: NEU), with its share price crashing 10.6% to an intra...

Motley Fool NEU 2 months ago
ASX Health Stocks: Neuren’s Q1 DAYBUE sales disappoint; 4DX gets another Medicare reimbursement in US

Neuren Pharma’s Q1 DAYBUE sales disappoint 4DMedical’s CT LVAS technology gets reimbursement in US Melodiol’s Canadian subsidiary, Mernova, continues to make strong progress   Neuren’s Q1 disappoints Neuren Pharma (ASX:NEU) slumped by ove...

Stockhead NEU 2 months ago
Neurotech reports positive top-line Phase 1/2 Rett Syndrome clinical trial results

Neurotech’s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug Company’s NTI164 compares favourably to DAYBUE, the only FDA-approved...

Stockhead NEU 3 months ago
Share tips – 8 April 2024

Share tips and stock recommendations for the Australian (ASX) share market – buy, hold, and sell. Michael Gable is an expert guest commentator for the stock market newsletter thebull.com.au. This post is an extract from the newsletter dated...

Fairmont Equities NEU 3 months ago